Compare BANR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | STOK |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1995 | 2019 |
| Metric | BANR | STOK |
|---|---|---|
| Price | $62.72 | $31.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $71.20 | $33.11 |
| AVG Volume (30 Days) | 187.3K | ★ 859.1K |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | ★ 5.49 | 0.68 |
| Revenue | ★ $640,027,000.00 | $205,632,000.00 |
| Revenue This Year | $0.96 | $430.24 |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ $11.42 | $46.36 |
| Revenue Growth | 7.86 | ★ 1128.17 |
| 52 Week Low | $54.01 | $5.35 |
| 52 Week High | $72.58 | $38.69 |
| Indicator | BANR | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 51.79 |
| Support Level | $66.40 | $31.00 |
| Resistance Level | $67.95 | $33.90 |
| Average True Range (ATR) | 1.08 | 1.67 |
| MACD | -0.53 | -0.26 |
| Stochastic Oscillator | 2.35 | 17.61 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.